3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Brain Neoplasms
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasm Metastasis
2
Wilms Tumor
1
Solid Tumors
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
9
Cyclophosphamide
8
Specimen Handling
7
X-Rays
6
Phantoms, Imaging
6
Vincristine
5
Nuclear Medicine Department, Hospital
5
Cisplatin
5
Temozolomide
4
Radiotherapy
4
Biopsy
4
Lomustine
3
Etoposide
3
Carboplatin
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
pembrolizumab
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Radiation
2
Platinum
2
Irinotecan
2
1,2-diaminocyclohexaneplatinum II citrate
2
tazemetostat
1
omburtamab I-131
1
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Medulloblastoma
×
entrectinib
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA